MEM 1003

Drug Profile

MEM 1003

Alternative Names: BAY Z 4406

Latest Information Update: 22 Mar 2010

Price : $50

At a glance

  • Originator Bayer
  • Developer Memory Pharmaceuticals
  • Class Antidementias; Dihydropyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Bipolar disorders; Mild cognitive impairment; Vascular dementia

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in cognitive decline and Alzheimer's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 18 Oct 2007 Final results from a phase IIa clinical trial in patients with Alzheimer's disease added to the adverse events and Alzheimier's Disease therapeutic trials sections
  • 11 Apr 2007 Memory Pharmaceuticals completes enrolment in its phase IIa trial for Alzheimer's Disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top